Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Bio Essence Corporation

Healthcare US BIOE

0.182USD
0.00(0%)

Last update at 2026-06-18T20:00:00Z

Day Range

0.180.25
LowHigh

52 Week Range

0.050.40
LowHigh

Fundamentals

  • Previous Close 0.18
  • Market Cap15.20M
  • Volume16761
  • P/E Ratio20.00
  • Dividend Yield-%
  • EBITDA0.90M
  • Revenue TTM1.90M
  • Revenue Per Share TTM0.05
  • Gross Profit TTM 1.43M
  • Diluted EPS TTM0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 0.90M -1.56492M -0.80015M -0.80638M -0.64426M
Minority interest - - - - -
Net income 0.90M -1.30880M -0.97188M -0.80968M -0.64756M
Selling general administrative 0.50M 0.68M 0.97M 1.17M 1.15M
Selling and marketing expenses 0.03M - 0.09M - -
Gross profit 1.43M 0.22M 0.28M 0.38M 0.30M
Reconciled depreciation 0.00023M 0.00091M 0.02M 0.05M 0.04M
Ebit 0.90M -1.56277M -0.78257M - -0.85753M
Ebitda 0.90M -1.56162M -0.76515M -0.72936M -0.56990M
Depreciation and amortization 0.00023M 0.00115M 0.02M - -
Non operating income net other - - - - -
Operating income 0.90M -0.45944M -0.78905M -0.78280M -0.84891M
Other operating expenses 1.00M 0.78M 1.34M - -
Interest expense 0.00219M 0.00215M 0.02M 0.02M 0.04M
Tax provision 0.00080M 0.00080M 0.00240M 0.00330M 0.00330M
Interest income - - - - -
Net interest income -0.00219M -0.00215M -0.01734M -0.02837M -0.04826M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00080M 0.00080M 0.00240M - 0.00330M
Total revenue 1.90M 0.32M 0.55M 0.99M 0.89M
Total operating expenses 0.53M 0.68M 1.07M 1.77M 1.74M
Cost of revenue 0.47M 0.11M 0.27M 0.60M 0.59M
Total other income expense net -0.00301M -1.10548M -0.01110M 0.00480M 0.25M
Discontinued operations - - - - -
Net income from continuing ops 0.90M -1.56572M -0.80255M -0.80968M -0.64756M
Net income applicable to common shares - - - - -0.64756M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 0.42M 0.28M 2.66M 1.55M 1.70M
Intangible assets 0.00010M 0.00033M 0.00057M 0.00080M 0.00104M
Earning assets - - - - -
Other current assets 0.40M 0.27M 0.00563M - -
Total liab 2.50M 3.25M 4.32M 4.79M 4.13M
Total stockholder equity -2.07289M -2.96909M -1.66029M -3.23841M -2.42874M
Deferred long term liab - - - - -
Other current liab 0.04M 0.34M 0.67M - 0.07M
Common stock 0.00380M 0.00380M 0.00380M - 0.00330M
Capital stock 0.00380M 0.00380M 0.00380M 0.00330M 0.00330M
Retained earnings -9.55307M -10.44927M -9.14047M -8.16859M -7.35892M
Other liab - - - - -
Good will - - - - -
Other assets - - - - 0.04M
Cash 0.00000M 0.00137M 0.00011M 0.00626M 0.00030M
Cash and equivalents - - - - -
Total current liabilities 2.44M 2.80M 3.18M 3.56M 2.76M
Current deferred revenue 0.85M 0.19M - - -
Net debt 1.56M 2.70M 3.48M 3.45M 2.68M
Short term debt 1.51M 2.26M 2.34M - -
Short long term debt 0.00286M 1.19M 1.84M 3.22M 2.43M
Short long term debt total 1.56M 2.70M 3.48M - -
Other stockholder equity 7.48M 7.48M 7.48M - -
Property plant equipment - - - - 1.39M
Total current assets 0.42M 0.28M 1.10M 0.20M 0.26M
Long term investments - - - - -
Net tangible assets - - - - -2.42977M
Short term investments - - - - -
Net receivables 0.02M 0.00512M 0.95M 0.00560M 0.02M
Long term debt 0.06M 0.06M 0.20M 0.24M 0.25M
Inventory - - 0.14M 0.18M 0.21M
Accounts payable 0.05M 0.02M 0.17M 0.05M 0.06M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 0.09M - -
Deferred long term asset charges - - - - -
Non current assets total 0.00010M 0.00033M 1.56M 1.34M 1.44M
Capital lease obligations 1.50M 1.46M 1.44M 1.16M 1.28M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.00011M -0.09148M -0.05912M -0.11680M
Change to liabilities - - - - 0.01M
Total cashflows from investing activities - -0.00011M -0.09148M - -0.11680M
Net borrowings -1.67112M -0.61317M 1.18M - 1.41M
Total cash from financing activities -1.57112M -0.62249M 1.11M 0.77M 1.41M
Change to operating activities - - - - -0.76144M
Net income 0.90M -1.30880M -0.80255M -0.80968M -0.64756M
Change in cash -0.00137M 0.00126M -0.00615M 0.00596M -0.00502M
Begin period cash flow 0.00137M 0.00011M 0.00626M 0.00030M 0.00532M
End period cash flow 0.00000M 0.00137M 0.00011M 0.00626M 0.00030M
Total cash from operating activities 1.57M 0.62M -1.02567M -0.70682M -1.29412M
Issuance of capital stock - - - - -
Depreciation 0.00023M 0.00091M 0.02M 0.05M 0.04M
Other cashflows from investing activities - -0.00011M -0.08787M - -
Dividends paid - - - - -
Change to inventory - - -0.01009M 0.03M 0.06M
Change to account receivables 0.18M 0.50M -0.00579M 0.01M 0.02M
Sale purchase of stock - - - - -
Other cashflows from financing activities -1.57112M -0.00932M -0.03638M - -
Change to netincome - - - - -0.00621M
Capital expenditures 0.00000M 0.00001M 0.00361M 0.06M 0.12M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.63M 0.87M -0.06844M 0.07M -0.45041M
Stock based compensation - - - - 0.00000M
Other non cash items 0.04M 1.07M -0.17210M -0.01672M -0.23947M
Free cash flow 1.57M 0.62M -1.02929M -0.76594M -1.41361M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BIOE
Bio Essence Corporation		 - -% 0.18 20.00 - 8.01 - 8.84 18.64
ZTS
Zoetis Inc		 -2.82 3.58% 75.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 - -% 42.94 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Bio Essence Corporation engages in the manufacturing and distributing health supplement products. It also offers original equipment manufacturing services. Bio Essence Corporation was incorporated in 2000 and is headquartered in Irvine, California.

Bio Essence Corporation

2955 Main Street, Irvine, CA, United States, 92618

Key Executives

Name Title Year Born
Ms. Yin Yan CEO, CFO & Chairman 1975
Mr. Tuan Tran VP of Operations 1975
Ms. Yin Yan CEO, Chief Accounting Officer & Chairman of the Board 1976
Yuling Huang Accounting Manager NA
Ji Ping Rong Operation Manager NA
Mr. William E. Sluss CFO & Director 1955
Mr. Tuan Tran Vice President of Operations 1974
Ms. Yin Yan J.D., M.B.A. CEO, Controller, Chief Accounting Officer & Chairman of the Board 1976
Wenwen He Accounting Assistant NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.